Equity · Healthcare

ZLAB

Zai Lab Limited · NasdaqGM

$20 −3.66% 1D Finazon · prior-day close · Jul 17, 2026

Price · Chart

Our own end-of-day closes 25 sessions

$21 $17 11 Jun 17 Jul

The line runs $18 on 11 June through $20 on 17 July, on a scale from $17 to $21. Days the market did not trade hold the previous close, flat.

The chart above plots the price of ZLAB over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 25 sessions over that window: $18 on 11 June 2026 through $20 on 17 July 2026.

Market cap $22.2B

52-week range $16.32 – $40.56

Avg volume 216.8K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026

About Zai Lab Limited

Zai Lab Limited is a commercial-stage global biopharmaceutical company with operations in Greater China and the United States. The company develops, discovers, and commercializes products in oncology, immunology, neuroscience, and infectious disease, and currently has seven commercial programs with products approved and launched in one or more territories in Greater China. Zai Lab markets these products through its own commercial infrastructure and has established partnerships with global biopharmaceutical companies for product development and commercialization.

Company

Headquarters Shanghai

Exchange NasdaqGM

Sector Healthcare

Class Equity

Website zailaboratory.com

ZLAB insider trades

SEC Form 4 · last 90 days · newest reported trade 19 Aug 2026

Open-market buys 1

Open-market sells 8

Net sold $999K

Non-trade filings 18

Date Insider Type Shares Value

19 Aug 2026 Chen Yajing Chief Financial Officer Sell 260 $7K

12 Aug 2026 Lis William Director Sell 8,506 $213K

11 Aug 2026 Chen Yajing Chief Financial Officer Sell 619 $15K

01 Jul 2026 GAYNOR RICHARD Director Buy 1,736 $33K

30 Jun 2026 Du Ying Chairperson & CEO Sell 7,026 $130K

26 Jun 2026 Chen Yajing Chief Financial Officer Sell 2,264 $40K

26 Jun 2026 Du Ying Chairperson & CEO Sell 24,543 $429K

26 Jun 2026 Edmondson Frazor Titus III Chief Legal Officer Sell 4,103 $72K

22 Jun 2026 Lis William Director Sell 7,040 $127K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value

14 Aug 2026 Chen Yajing Chief Financial Officer Option exercise 1,250

14 Aug 2026 Chen Yajing Chief Financial Officer Tax withheld 427 $11K

02 Jul 2026 Du Ying Chairperson & CEO Option exercise 11,048

02 Jul 2026 Du Ying Chairperson & CEO Tax withheld 4,348 $83K

01 Jul 2026 Du Ying Chairperson & CEO Option exercise 18,000

01 Jul 2026 Du Ying Chairperson & CEO Tax withheld 7,083 $136K

29 Jun 2026 Du Ying Chairperson & CEO Option exercise 17,970

25 Jun 2026 Chen Yajing Chief Financial Officer Option exercise 6,250

25 Jun 2026 Du Ying Chairperson & CEO Option exercise 58,800

25 Jun 2026 Edmondson Frazor Titus III Chief Legal Officer Option exercise 14,600

17 Jun 2026 DIEKMAN JOHN D Director Award 22,371

17 Jun 2026 GAYNOR RICHARD Director Award 22,371

Showing the 12 most recent of 18 compensation filings in this window. The figures above count all of them.

ZLAB earnings

SEC EDGAR

Date Period EPS Revenue

30 Jun 2026 Q2 2026 $-0.05 $106M

31 Mar 2026 Q1 2026 $-0.05 $100M

31 Dec 2025 FY 2025 $-0.16 $460M

30 Sep 2025 Q3 2025 $-0.03 $116M

30 Jun 2025 Q2 2025 $-0.04 $110M

31 Mar 2025 Q1 2025 $-0.04 $106M

31 Dec 2024 FY 2024 $-0.26 $399M

30 Sep 2024 Q3 2024 $-0.04 $102M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ZLAB

ZLAB insider trades

ZLAB reported financials

ZLAB earnings

ZLAB institutional holders

ZLAB fails-to-deliver